Tier 2 — strong

Bioavailability of quercetin in humans and the influence of food matrix comparing quercetin capsules and different apple sources

Beate Petersen, Sarah Egert, Anja Bosy-Westphal, Manfred J Müller, Siegfried Wolffram, Eva M Hubbermann, Gerald Rimbach, Karin Schwarz
Food research international (Ottawa, Ont.) 2016 88(Pt A):159-165

Bibliography

PubMed
PMID 28847395
DOI
10.1016/j.foodres.2016.02.013
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignFour-way crossover food-matrix absorption pilot
ModelHuman intervention research
Sample6 healthy volunteers
InterventionApple chips, apple peel, apple-extract capsules, or quercetin-dihydrate capsules, providing 71 micromol quercetin equivalents
DurationAcute dietary comparisons
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2016, this source examined forms, absorption and food sources. Design: Four-way crossover food-matrix absorption pilot. Sample/model: 6 healthy volunteers. The exposure or intervention was Apple chips, apple peel, apple-extract capsules, or quercetin-dihydrate capsules, providing 71 micromol quercetin equivalents. Follow-up or treatment period: Acute dietary comparisons.

The tested apple preparations and reference capsule produced broadly similar exposure, with matrix-related differences in concentration profiles.

Very small formulation study. The result cannot be generalized to all apples, extracts, or capsule products, and no clinical benefit was assessed.

Continue with Quercetin Data Center

For topic-level interpretation, read Foods High in Quercetin: Practical Sources and Portions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The tested apple preparations and reference capsule produced broadly similar exposure, with matrix-related differences in concentration profiles.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Apple chips, apple peel, apple-extract capsules, or quercetin-dihydrate capsules, providing 71 micromol quercetin equivalents; Acute dietary comparisons.

What this study can and cannot tell us

  • Very small formulation study. The result cannot be generalized to all apples, extracts, or capsule products, and no clinical benefit was assessed.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology